Citations

  1. Sharma et al 2010 "A chromatin-mediated reversible drug-tolerant state in cancer cell subpopulations," Cell 141(1):69-80

  2. Witta et al, 2006 "Restoring E-cadherin expression increases sensitivity to epidermal growth factor receptor inhibitors in lung cancer cell lines," Cancer Research 66(2):944-50

  3. Sabnis, G., O. Golobeva, et al. (2010). "HDAC inhibitor entinostat restores responsiveness of letrozole resistant MCF-7Ca xenografts to AIs through Modulation of Her-2." SABCS poster.

  4. Brodie, A., L. Macedo, et al. (2010). "Aromatase resistance mechanisms in model systems in vivo." J Steroid Biochem Mol Biol. 118:283-87.

  5. Sharma et al 2010 "A chromatin-mediated reversible drug-tolerant state in cancer cell subpopulations," Cell 141(1):69-80

  6. Glasspool et al 2006 "Epigenetics as a mechanism driving polygenic clinical drug resistance," British Journal of Cancer 94(8):1087-92

  7. Lane and Chabner 2009 "Histone deacetylase inhibitors in cancer therapy," Journal of Clinical Oncology 27(32):5459-68

  8. Hurvitz, S, Pietras, R. Rational Management of Endocrine Resistance in Breast Cancer, Cancer, 2385- 2397 (2008).

  9. Huang, Xiaoping, Gao, Lizhi, Wang, Shuiliang, Lee, Choon-Kee, Ordentlich, Peter, and Liu, Bolin. HDAC Inhibitor SNDX-275 Induces Apoptosis in erbB2-Overexpressing Breast Cancer Cells via Down-regulation of erbB3 Expression, Cancer Res, 8403- 8411 (2009).

  10. Sabnis, Gauri, 2009 "Expression of ERa and Aromatase in MDA-MB-231 Tumors by HDAC Inhibitor Entinostat Leads to Growth Inhibition by Aromatase Inhibitor Letrozole," San Antonio Breast Cancer Symposium, San Antonio, TX.

  11. Cho, S 2008 “Risk of Recurrence in Surgically Resected Stage I Adenocarcinoma of the Lung: Histopathologic and Immunohistochemical Analysis,” Lung. 10.1007/s00408-008-9116-4.